Q4 FY2025 · Press release
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration · 2 pages
Read Ocugen, Inc.'s results firsthand
Preview this press release
Create a free account to start reading
Full documents are included with Professional